Hut Alexandru-Romulus, Boia Eugen Radu, Para Diana, Iovanescu Gheorghe, Horhat Delia, Mikša Loredan, Chiriac Maria, Galant Raphaël, Motofelea Alexandru Catalin, Balica Nicolae Constantin
Department of Doctoral Studies, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
ENT Department, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
J Clin Med. 2025 May 12;14(10):3367. doi: 10.3390/jcm14103367.
: Laryngeal cancer (LC), predominantly squamous cell carcinoma (SCC), represents a considerable health burden worldwide. Tumour subsite heterogeneity (supraglottic, glottic, subglottic) influences clinical behavior and outcomes. This review synthesizes current knowledge on epidemiology, risk factors, diagnostics, histological variants, biomarkers, treatment modalities, and survival. : This narrative review synthesizes current literature on the epidemiology, risk factors, diagnosis, histological variants, biomarkers, and prognosis of LC. The review highlights the critical influence of tumour sites (supraglottic, glottic, subglottic) on metastatic patterns and survival. Key risk factors of LC include tobacco and alcohol use, human papillomavirus (HPV) infection, and occupational exposures. The diagnostic process encompasses clinical examination, endoscopy, biopsy, and imaging. Several biomarkers that aid in diagnosis, treatment plan determination, and prognosis prediction have been established. These biomarkers include long noncoding RNAs, cell cycle regulators, apoptosis regulators, oncogenes, tumour suppressor genes, growth factor pathway components, angiogenic factors, structural proteins, sex hormone receptors, and immunological markers. Current treatment modalities range from organ-preserving surgery and radiotherapy to combined chemoradiotherapy and total laryngectomy. Finally, survival data are presented and stratified by stage and subsite. : The review underscores the need for a multidisciplinary approach to LC management, integrating clinical, pathological, and molecular information to optimize patient outcomes.
喉癌(LC),主要为鳞状细胞癌(SCC),在全球范围内构成了相当大的健康负担。肿瘤亚部位异质性(声门上型、声门型、声门下型)会影响临床行为和预后。本综述综合了当前关于流行病学、危险因素、诊断、组织学变异、生物标志物、治疗方式及生存率的知识。:本叙述性综述综合了关于喉癌流行病学、危险因素、诊断、组织学变异、生物标志物及预后的当前文献。该综述强调了肿瘤部位(声门上型、声门型、声门下型)对转移模式和生存率的关键影响。喉癌的主要危险因素包括吸烟、饮酒、人乳头瘤病毒(HPV)感染及职业暴露。诊断过程包括临床检查、内镜检查、活检及影像学检查。已经确立了几种有助于诊断、确定治疗方案及预测预后的生物标志物。这些生物标志物包括长链非编码RNA、细胞周期调节因子、凋亡调节因子、癌基因、肿瘤抑制基因、生长因子通路成分、血管生成因子、结构蛋白、性激素受体及免疫标志物。当前的治疗方式从保留器官手术和放疗到联合放化疗及全喉切除术不等。最后,按分期和亚部位列出并分层呈现生存率数据。:该综述强调了对喉癌管理采取多学科方法的必要性,整合临床、病理及分子信息以优化患者预后。